Abbott Laboratories (ABT) Return on Equity (ROE): 12.06%
Is Abbott Laboratories’s return on equity (ROE) high or low?
Abbott Laboratories's return on equity (ROE) of 12.06% is 33% below its 5-year average of 17.97%, near the low end of its 5-year range (12.51%–28.12%).
The return on equity (ROE) for Abbott Laboratories (ABT) is 12.06% as of Wednesday, June 10, 2026. It is below its 12-month average by 40.63% (20.32%).
ABT Return on Equity (ROE) Chart
ABT Average Return on Equity (ROE) Chart
ABT Current vs Average Return on Equity (ROE) Chart
ABT Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
12.06%
RETURN ON EQUITY (ROE) AVG TTM
20.32%
RETURN ON EQUITY (ROE) AVG 3Y
18.59%
RETURN ON EQUITY (ROE) AVG 5Y
17.97%
RETURN ON EQUITY (ROE) AVG 10Y
14.24%
RETURN ON EQUITY (ROE) AVG 15Y
14.97%
RETURN ON EQUITY (ROE) AVG 20Y
16.58%
CURRENT VS TTM AVG
-40.63%
CURRENT VS 3Y AVG
-35.13%
CURRENT VS 5Y AVG
-32.89%
CURRENT VS 10Y AVG
-15.31%
CURRENT VS 15Y AVG
-19.45%
CURRENT VS 20Y AVG
-27.27%
ABT Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | — | 12.06% | 20.32% | 18.59% | 17.97% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 39.19% | 20.05% | 21.63% | 19.46% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 17.05% | 15.07% | 13.91% | 13.46% |
| Pfizer Inc. (PFE) | $146.36B | 8.31% | 9.04% | 13.32% | 16.07% |
| Danaher Corporation (DHR) | $130.25B | 6.97% | 7.38% | 9.51% | 10.24% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 13.21% | 12.70% | 13.51% | 15.24% |
| Amgen Inc. (AMGN) | $183.75B | 84.87% | 79.33% | 111.35% | 101.76% |
| CVS Health Corporation (CVS) | $125.16B | 3.79% | 4.23% | 6.35% | 7.74% |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 36.25% | -8.30% | 7.76% | 4.45% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 22.41% | 8.96% | 15.60% | 19.47% |
Return Analysis
ROE
12.1%
ROA
5.7%
Abbott Laboratories Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Abbott Laboratories Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Abbott Laboratories (ABT)?
- The return on equity (ROE) for ABT stock is 12.06%.
- Is Abbott Laboratories's return on equity (ROE) high or low?
- Abbott Laboratories's return on equity (ROE) of 12.06% is 33% below its 5-year average of 17.97%, near the low end of its 5-year range (12.51%–28.12%).
- What is the TTM average return on equity (ROE) for Abbott Laboratories (ABT)?
- The TTM average return on equity (ROE) for ABT stock is 20.32%.
- What is the 3Y average return on equity (ROE) for Abbott Laboratories (ABT)?
- The 3Y average return on equity (ROE) for ABT stock is 18.59%.
- What is the 5Y average return on equity (ROE) for Abbott Laboratories (ABT)?
- The 5Y average return on equity (ROE) for ABT stock is 17.97%.
- What is the 10Y average return on equity (ROE) for Abbott Laboratories (ABT)?
- The 10Y average return on equity (ROE) for ABT stock is 14.24%.
- What is the 15Y average return on equity (ROE) for Abbott Laboratories (ABT)?
- The 15Y average return on equity (ROE) for ABT stock is 14.97%.
- What is the 20Y average return on equity (ROE) for Abbott Laboratories (ABT)?
- The 20Y average return on equity (ROE) for ABT stock is 16.58%.
Abbott Laboratories Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 12.51% |
| 2024-12-31 | 28.12% |
| 2023-12-31 | 14.83% |
| 2022-12-31 | 18.90% |
| 2021-12-31 | 19.75% |
| 2020-12-31 | 13.71% |
| 2019-12-31 | 11.86% |
| 2018-12-31 | 7.76% |
| 2017-12-31 | 1.54% |
| 2016-12-31 | 6.82% |
| 2015-12-31 | 20.85% |
| 2014-12-31 | 10.61% |
| 2013-12-31 | 10.23% |
| 2012-12-31 | 22.32% |
| 2011-12-31 | 19.35% |
| 2010-12-31 | 20.40% |
| 2009-12-31 | 24.83% |
| 2008-12-31 | 27.92% |
| 2007-12-31 | 20.28% |
| 2006-12-31 | 12.22% |
| 2005-12-31 | 23.39% |
| 2004-12-31 | 22.59% |
| 2003-12-31 | 21.06% |
| 2002-12-31 | 26.20% |
| 2001-12-31 | 17.11% |
| 2000-12-31 | 32.51% |
| 1999-12-31 | 32.93% |
| 1998-12-31 | 40.86% |
| 1997-12-31 | 41.59% |
| 1996-12-31 | 39.04% |
Related Metrics
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford